Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer

被引：10
|
作者：
Reckamp, Karen L. [1 ,2 ]
机构：
[1] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA
来源：
CANCER LETTERS | 2012年 / 321卷 / 02期
关键词：
Angiogenesis; Non-small cell lung cancer; Tyrosine kinase inhibitor; Vascular disrupting agent; Second-line therapy; PHASE-III TRIAL; TRIPLE ANGIOKINASE INHIBITOR; DOUBLE-BLIND; KINASE INHIBITORS; ENDOTHELIAL-CELLS; 1ST-LINE THERAPY; BEVACIZUMAB; TUMOR; VEGF; SUNITINIB;
D O I：
10.1016/j.canlet.2012.01.041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With the approval of the antiangiogenic antibody bevacizumab in non-small cell lung cancer (NSCLC) and other malignancies, the tumor vasculature has emerged as a worthwhile therapeutic target. Second-line therapies have the potential to improve overall survival and quality of life over best supportive care alone. Accordingly, phase II and phase III studies are actively evaluating antiangiogenic treatments in the second-line setting in NSCLC, and results are awaited. Such therapies include antiangiogenic antibodies, small molecule inhibitors, and vascular-disrupting agents. This review will present the current landscape of angiogenesis inhibition in NSCLC, focusing on use as second-line therapy. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：101 / 109
页数：9
相关论文
共 50 条
  • [1] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    [J]. LUNG CANCER, 2009, 64 : S13 - S13
  • [2] Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting
    Reck, Martin
    Garassino, Marina Chiara
    Imbimbo, Martina
    Shepherd, Frances A.
    Socinski, Mark A.
    Shih, Jin-Yuan
    Tsao, Anne
    Lee, Pablo
    Winfree, Katherine B.
    Sashegyi, Andreas
    Cheng, Rebecca
    Varea, Rocio
    Levy, Benjamin
    Garon, Edward
    [J]. LUNG CANCER, 2018, 120 : 62 - 69
  • [3] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [4] Considerations for second-line therapy of non-small cell lung cancer
    Stinchcombe, Thomas E.
    Socinski, Mark A.
    [J]. ONCOLOGIST, 2008, 13 : 28 - 36
  • [5] Second-line therapy and advanced non-small cell lung cancer: What about smoking?
    Braillon, Alain
    [J]. LUNG CANCER, 2018, 122 : 257 - 257
  • [6] Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer
    Huber, R
    Schmidt, M
    Borgmeier, A
    [J]. LUNG CANCER, 2005, 49 : S248 - S248
  • [7] Single agents in the second-line treatment of non-small cell lung cancer
    Belani, CP
    [J]. SEMINARS IN ONCOLOGY, 1998, 25 (03) : 10 - 14
  • [8] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [9] Second-line treatment options in advanced non-small cell lung cancer
    de Marinis, Filippo
    Ricciardi, Serena
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S258 - S271
  • [10] Second-line therapy for advanced non-small-cell lung cancer
    Hann C.L.
    Brahmer J.R.
    [J]. Current Oncology Reports, 2006, 8 (4) : 243 - 247
12345